<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="552">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394442</url>
  </required_header>
  <id_info>
    <org_study_id>SNH1352020</org_study_id>
    <nct_id>NCT04394442</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine in COVID-19 Patients</brief_title>
  <official_title>Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samah Lutfy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many reports argued about the possible beneficial effects of Hydroxychloroquine in treating
      COVID-19 patients and this study was designed to investigate this claim
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to viral clearance</measure>
    <time_frame>21 days after patients randomization</time_frame>
    <description>PCR will be done every 72 h day till 2 consecutive negative PCR tests(24h apart) which is the viral clearance.The time between randomization and viral clearance is the viral clearance time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% of mortality</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>total number of deaths divided by total number of the group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>time from patients randomization till discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to be afebrile</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>time from randomization till day of fever subsiding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for mechanical ventilation</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>%of deteriorated patients necessitates mechanical ventilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Hydroxycholoroquine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>400mg BD first day then 200 mg BD for 5 days</description>
    <arm_group_label>Hydroxycholoroquine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Confirmed cases of SARS-CoV-2 by PCR

        Exclusion Criteria:

        less than 18 years old known hypersensitivity to the drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samah M Lutfy, MD</last_name>
    <phone>+966581244415</phone>
    <email>omar1star2008@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SNH</name>
      <address>
        <city>Mecca</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samah Lutfy, MD</last_name>
      <phone>+966581244415</phone>
      <email>omar1star2008@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 17, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Samah Lutfy</investigator_full_name>
    <investigator_title>Assistant professor of chest diseases</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

